Clinical efficacy of butadiphenylpeptide combined with aspirin and clopidogrel in the treatment of ACI
Objective:To analyze the clinical efficacy of butadiphenylpeptide combined with aspirin and clopidogrel in the treatment of acute cerebral infarction(ACI).Methods:The clinical data of 98 patients with ACI admitted to our hospital from December 2022 to June 2023 were retrospectively collected.According to different treatment methods,the patients were divided into control group(aspirin+clopidogrel,48 cases)and observation group(butadiphenylpeptide combined with aspirin+clopidogrel,50 cases).The clinical efficacy,neurological function and limb movement,coagulation function and incidence of adverse reactions were analyzed and compared between the two groups.Results:The clinical effect of observation group was significantly higher than that of control group(P<0.05).After treatment,NIHSS score was significantly decreased and FMA score was significantly increased in both groups,and NIHSS score in observation group was significantly lower than that in control group,FMA score was significantly higher than that in control group(P<0.05).After treatment,the FIB level of both groups showed a downward trend,and the APTT and PT levels showed an upward trend,and the decrease of FIB level in the observation group was significantly greater than that in the control group,and the increase of APTT and PT levels was significantly greater than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of butadiphenylpeptide combined with aspirin and clopidogrel can improve the clinical efficacy of ACI patients,promote the recovery of nerve function and limb motor function,improve coagulation function,and has a high safety.
NETL
NSTL
万方数据
